AU Patent

AU2023274224A1 — Process for preparing tapinarof

Assigned to Dermavant Sciences GmbH · Expires 2023-12-21 · 2y expired

What this patent protects

The present invention provides processes for the preparation of 3, 5-Dihydroxy-4-isopropyl trans-stilbene or a salt or solvate thereof and novel intermediates used therein. In some embodiments the 3, 5-Dihydroxy-4-isopropyl-trans-stilbene is prepared from (E)-2-chloro-2 isopropy…

USPTO Abstract

The present invention provides processes for the preparation of 3, 5-Dihydroxy-4-isopropyl trans-stilbene or a salt or solvate thereof and novel intermediates used therein. In some embodiments the 3, 5-Dihydroxy-4-isopropyl-trans-stilbene is prepared from (E)-2-chloro-2 isopropyl-5-styrylcyclohexane-1,3-dione. Also disclosed are crystal forms of 3, 5-Dihydroxy 4-isopropyl-trans-stilbene or a salt or solvate thereof and pharmaceutical compositions comprising same. See Fig. 1.

Drugs covered by this patent

Patent Metadata

Patent number
AU2023274224A1
Jurisdiction
AU
Classification
—
Expires
2023-12-21
Drug substance claim
No
Drug product claim
No
Assignee
Dermavant Sciences GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.